10 new cancer drug highlights for ASCO

22nd May 2015

10 new cancer drug highlights for ASCOAndrew McConaghie

Researchers are set to reveal the latest good news in cancer research – but questions about price and value won't be far away, reports Andrew McConaghie.The countdown has begun to... Read more

Successful brand building means solving customer problems

21st May 2015

Successful brand building means solving customer problemsKim Hughes

Pharma marketers need to listen to HCPs and patients to find out what issues they face and then position products to meet these needs.In a recent presentation Michael Holgate, founding... Read more

Ending the neglect of mental health: can the NHS do it?

20th May 2015

Ending the neglect of mental health: can the NHS do it?Andrew McConaghie

The Conservatives promise to put mental health services on a par with physical healthcare – but more austerity is a major threat, reports Andrew McConaghie.Amid the general election's war of... Read more

Mental health improvements must go much further, much faster

20th May 2015

Mental health improvements must go much further, much fasterPaul Farmer

Paul Farmer, Mind CEO, outlines the charity's priorities over the next five years, his concerns about funding and his views on where the new Government should be concentrating its efforts... Read more


Is a deal to create 'PfizerKline' in the offing?

22nd May 2015

Is a deal to create 'PfizerKline' in the offing?Staff reporter

The rumour mill has been grinding away furiously in the last few days, focusing mainly on a possible bid for GlaxoSmithKline (GSK) by Pfizer.The speculation about a deal to create... Read more

NICE to launch ‘Office for Market Access’

22nd May 2015

NICE to launch ‘Office for Market Access’Andrew McConaghie

NICE is to establish a new Office for Market Access to help life sciences companies prepare for its cost effectiveness appraisals and improve their chances of gaining a 'yes'.The new... Read more

J&J plans to file 10 new blockbusters by 2019

21st May 2015

J&J plans to file 10 new blockbusters by 2019Staff reporter

For years, the pharma industry has been saying the era of the blockbuster product is over, but Johnson & Johnson (J&J) is clearly not of that mind.At a strategy meeting... Read more

Circassia leads UK biotech funding success

20th May 2015

Circassia leads UK biotech funding successStaff reporter

Three separate fund-raising rounds - headed by Circassia's £275 million placing and open offer - give a further indication of the revival in the UK biopharma sector.Circassia plans to the... Read more

Audio & Video

Available on demand: Exclusive debate/we…



The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…


Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

On demand webinar: Staring into the aby…

IMS webinar


Regardless of the colour of the next UK government that emerges as a result of the May election, the £30–50bn NHS budget... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate



COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

White Papers

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

Further News & Articles

Boehringer licenses liver disease candidate

Boehringer Ingelheim (BI) has licensed a drug for non-alcoholic fatty liver diseases from Australia's Pharmaxis,... Read more


Data, ethics and anonymisation in a changing digital communications world

This is the last in a series of three articles examining the legal and ethical dilemmas faced when using new medi... Read more


More data backs Orkambi benefit in cystic fibrosis

Vertex is just a few weeks away from hearing the FDA's verdict on its cystic fibrosis (CF) therapy Orkambi, so t... Read more


FDA warns on AZ, Lilly and J&J diabetes drug safety

The FDA has warned that patients taking a newer class of diabetes drugs may cause dangerously high level of bloo... Read more


The future is small: how startups drive innovation

Through forging better understanding of one another's needs, pharma and innovative informatics startups can colla... Read more


BMS and AbbVie's elotuzumab could be game changer in myeloma

A phase III trial of Bristol-Myers Squibb's (BMS) and AbbVie's multiple myeloma therapy elotuzumab has been flagged by t... Read more